384 related articles for article (PubMed ID: 28502238)
1. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
[TBL] [Abstract][Full Text] [Related]
2. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K; Lee SH; Cheng Z; Lakshminarayanan P; Peng L; Han P; McNutt TR; Quon H; Lee J
Radiat Oncol; 2019 Jul; 14(1):131. PubMed ID: 31358029
[TBL] [Abstract][Full Text] [Related]
3. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
[TBL] [Abstract][Full Text] [Related]
4. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
[TBL] [Abstract][Full Text] [Related]
5. [Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].
Kuhnt T; Jirsak N; Müller AC; Pelz T; Gernhardt C; Schaller HG; Janich M; Gerlach R; Dunst J
Strahlenther Onkol; 2005 Aug; 181(8):520-8. PubMed ID: 16044220
[TBL] [Abstract][Full Text] [Related]
6. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.
Dijkema T; Terhaard CH; Roesink JM; Braam PM; van Gils CH; Moerland MA; Raaijmakers CP
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1101-9. PubMed ID: 18472355
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy.
Lee TF; Fang FM
Radiother Oncol; 2013 Mar; 106(3):352-8. PubMed ID: 23333019
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
[TBL] [Abstract][Full Text] [Related]
9. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
[TBL] [Abstract][Full Text] [Related]
11. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
[TBL] [Abstract][Full Text] [Related]
12. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
[TBL] [Abstract][Full Text] [Related]
13. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
14. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT.
Nardone V; Tini P; Nioche C; Mazzei MA; Carfagno T; Battaglia G; Pastina P; Grassi R; Sebaste L; Pirtoli L
Radiol Med; 2018 Jun; 123(6):415-423. PubMed ID: 29368244
[TBL] [Abstract][Full Text] [Related]
15. Volumetric changes of the parotid gland during IMRT based on mid-treatment imaging: implications for parotid stem cell sparing strategies in head and neck cancer.
Gjini M; Ahmed S; Kalnicki S; Tomé WA; Garg MK; Kabarriti R; Brodin NP
Acta Oncol; 2022 Sep; 61(9):1069-1074. PubMed ID: 35978529
[TBL] [Abstract][Full Text] [Related]
16. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
[TBL] [Abstract][Full Text] [Related]
17. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy.
Marzi S; Iaccarino G; Pasciuti K; Soriani A; Benassi M; Arcangeli G; Giovinazzo G; Benassi M; Marucci L
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1252-9. PubMed ID: 19251097
[TBL] [Abstract][Full Text] [Related]
18. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
19. A comparison of dose-response models for the parotid gland in a large group of head-and-neck cancer patients.
Houweling AC; Philippens ME; Dijkema T; Roesink JM; Terhaard CH; Schilstra C; Ten Haken RK; Eisbruch A; Raaijmakers CP
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1259-65. PubMed ID: 20005639
[TBL] [Abstract][Full Text] [Related]
20. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]